Ablynx N.V. (NASDAQ:ABLYF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.
According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “
Ablynx N.V. (ABLYF) traded up 1.19% during midday trading on Monday, hitting $15.28. The company had a trading volume of 200 shares. Ablynx N.V. has a 52 week low of $9.10 and a 52 week high of $50.00. The stock has a 50 day moving average price of $14.41 and a 200-day moving average price of $13.01. The stock’s market capitalization is $921.31 million.
Receive News & Ratings for Ablynx N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ablynx N.V. and related companies with MarketBeat.com's FREE daily email newsletter.